Given that intranasal insulin bypasses the BBB to enter the brain with negligible systemic consequences, there has been much interest in the use of intranasal insulin to treat individuals with cognitive decline, obesity/type 2 diabetes and mood disorders [174,175]. The gene discussed is INS; the disease is type 2 diabetes mellitus.